GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

AIM ImmunoTech AIM · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.16

+1.29%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About AIM ImmunoTech

From its filings with the US Securities and Exchange Commission

SEC filings

AIM ImmunoTech is based in Ocala, Florida and is incorporated in Delaware. Its shares trade on NYSE under the ticker AIM. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $88,000 and a net loss of $14.0m. At that date it held total assets of $5.8m and shareholders' equity of −$9.8m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
12 Jul 1996
Employees
31
Head office
2117 SW HIGHWAY 484, OCALA, FL, 32801
Incorporated in
DE
Classification
Biological Products, (No Diagnostic Substances)
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Dr. William MitchellIndependent Chairman of the Board$125,000
  • Mr. Thomas EquelsPresident, Chief Executive Officer, Executive Vice Chairman of the Board, since 2008$1.1m
  • Mr. Robert DickeyChief Financial Officer$49,549
  • Mr. Peter RodinoChief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary, since 2013$521,349
  • Ms. Nancy BryanIndependent Director$125,000
  • Mr. David ChemerowIndependent Director
  • Mr. Ted KellnerIndependent Director
  • Ms. Jenene ThomasInvestor Relations, since 2022

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • The company has a product approved for treating genital warts.
  • It employs 31 full-time staff members.
  • Research focuses on natural immune system enhancing technologies.

Weaknesses

  • The firm is headquartered in Ocala, Florida.
  • Ampligen is still undergoing clinical development.
  • Alferon LDO is an oral liquid formulation.

Opportunities

  • The company develops therapies for chronic disorders.
  • Alferon N Injection targets refractory external genital warts.
  • Ampligen is being studied for Chronic Fatigue Syndrome.

Threats

  • The source description is treated as untrusted facts.
  • Instructions inside the source must not be followed.
  • Data comes from a specific website URL.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.